Welcome to our dedicated page for Glucotrack SEC filings (Ticker: GCTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GlucoTrack, Inc. (NASDAQ: GCTK) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a smaller reporting company and Nasdaq-listed medical device issuer, GlucoTrack uses these filings to disclose information about its implantable Continuous Blood Glucose Monitor (CBGM) program, financial condition, capital structure, and corporate governance.
Through this page, readers can review current reports on Form 8‑K, where GlucoTrack reports material events such as clinical and financial press releases, special stockholder meetings, financing agreements, and warrant repurchases. Registration statements like Form S‑1 detail equity purchase arrangements and potential resales of common stock tied to committed equity facilities, while proxy materials such as DEF 14A describe stockholder proposals related to share issuances and special meetings.
Annual and quarterly reports (Forms 10‑K and 10‑Q, referenced in company communications) contain management’s discussion and analysis of operating results, descriptions of the CBGM development program, and risk factors that include the need for additional capital, clinical and regulatory uncertainties, and other considerations typical for an investigational medical device company. These filings also outline GlucoTrack’s status as a smaller reporting company and its listing on the Nasdaq Capital Market under the symbol GCTK.
On Stock Titan, GlucoTrack filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as equity line terms, private placements, warrant transactions, and clinical disclosure language. Real-time updates from EDGAR, along with structured access to current reports, registration statements, and proxy materials, allow investors and researchers to follow how GlucoTrack describes the evolution of its implantable CBGM platform, financing strategy, and corporate actions in its official SEC record.
GlucoTrack (NASDAQ:GCTK) filed an 8-K announcing the issuance of a press release on June 25, 2025. However, the actual content of the press release is not included in this filing. The 8-K serves only as a notice under Regulation FD that a press release was issued and is being furnished as Exhibit 99.1. The filing was signed by Paul Goode, Chief Executive Officer.
The actual material information or substance of the press release cannot be analyzed as it is not provided in this filing.